| Company/Division name | CoImmune |
| Parent company | SCM Life Science |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Capital investment ($): | 11.1 |
| Country(ies) from which reshored: | Korea, Republic of |
| City reshored to: | Durham |
| State(s) reshored to: | NC |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | immunotherapies |
| What domestic positive factors made reshoring more attractive? | Automation/technology, Proximity to customers/market, Under-utilized capacity |
